GleamWall
中文EN

NCNA NuCana plc IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-54.5%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-193.9%
ROA-131.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.60x
Interest coverage-1.59x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-98.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: GBP 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-302022Q2*2022-06-302021Q4*2021-12-312021Q3*2021-09-302021Q2*2021-06-302021Q1*2021-03-31
Income statement
Revenue————————
R&D expense7.10M6.77M3.96M6.41M10.63M8.97M8.52M8.71M
Operating income-11.83M-8.35M-6.28M-5.22M-15.74M-9.97M-10.71M-11.49M
Interest expense12.65M0——————
Pretax income-24.44M-8.27M-6.10M-5.09M-15.71M-9.95M-10.67M-11.46M
Income tax-328,000-1.27M-685,000-1.19M-2.07M-1.91M-1.58M-1.70M
Net income-24.11M-7.00M-5.41M-3.89M-13.64M-8.04M-9.09M-9.76M
EBITDA————-15.47M-9.74M-10.48M-11.27M
EPS (basic)0.00-0.12-0.10-0.07—-0.15-0.17-0.19
EPS (diluted)0.00-0.12-0.10-0.07—-0.15-0.17-0.19
Balance sheet
Cash & equivalents8.44M11.64M24.64M46.53M60.26M71.03M73.42M78.62M
Receivables1.02M2.04M2.62M3.93M4.16M5.13M4.20M4.81M
Current assets13.73M17.34M37.89M60.87M71.61M81.30M86.43M94.97M
PP&E, netmay include right-of-use assets (IFRS)178,000343,000701,000613,000851,000952,0001.04M1.10M
Intangibles2.20M2.21M2.55M2.47M2.41M4.90M4.81M4.76M
Total assets16.22M20.07M41.26M66.63M77.47M89.78M92.32M100.87M
Current liabilities8.70M16.06M13.54M10.43M11.72M12.10M7.86M9.07M
Total liabilities8.83M16.27M13.88M10.60M11.93M12.34M8.13M9.41M
Shareholders' equity7.38M3.80M27.38M56.03M65.55M77.45M84.19M91.46M
Cash flow statement
Operating cash flow————-10.09M-805,000-4.86M-8.07M
Capital expenditure————21,0006,00033,0004,000
Free cash flow————-10.11M-811,000-4.89M-8.08M
Investing cash flow————-463,000-2.80M-180,000-118,000
Financing cash flow————-74,000-74,000-74,000124,000
Depreciation & amortization————269,000229,000222,000222,000
Stock-based compensation8.00M700,0001.10M1.20M1.75M1.30M1.80M1.79M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.